CVM's been trying the same product against all sorts of diseases, each time they fail they just name a new disease and start all over again with a lot of newly issued shares. I did invest decades ago when AIDS was their target, and they'd changed their symbol to HIV. The one thing CVM knows how to do is cut and pastes, they just change the name of the disease and reissue all the PR's they've issued in the past. Once a product's proven not to be harmful the FDA doesn't care how companies spend their money in trying it. Maybe some day their cure will find it's disease.
They are already close to 2.35B shares if you consider 339M highlighted in Form S-1 last month (notes and warrants). And also another 350M+ held by execs in options, etc. So probably 250M more to go before they beg again to increase the authorized share count. But there will be no big pharma partner. Have fun! ;)
Market Data 
Markets 
AI
